en 30090214 <p>Background: It is more than sixty years that the concept of the fetal allograft and immunological paradox of pregnancy was proposed and in this context, several regulatory networks and mechanisms have been introduced so far. It is now generally recognized that mesenchymal stem cells exert potent immunoregulatory activity. In this study, for the first time, the potential impact of Menstrual blood Stem Cells (MenSCs), as surrogate for endometrial stem cells, on proliferative capacity of CD4+ T cells was tested.<br /> Methods: MenSCs and Bone marrow Mesenchymal Stem Cells (BMSCs) were isolated and assessed for their immunophenotypic features and multi-lineage differentiation capability. BMSCs and MenSCs with or without IFN&gamma; pre-stimulation were co-cultured with purified anti-CD3/CD28-activated CD4+ T cells and the extent of T cell proliferation at different MenSCs: T cell ratios were investigated by CSFE flow cytometry. IDO activity of both cell types was measured after stimulation with IFN&gamma; by a colorimetric assay.<br /> Results: MenSCs exhibited dual mesenchymal and embryonic markers and multi-lineage differentiation capacity. MenSCs significantly increased proliferation of CD4+ cells at ratios 1:2, 1:4 and 1:8. IFN&gamma; pre-treated BMSCs but not MenSCs significantly suppressed CD4+ T cells proliferation. Such proliferation promoting capacity of MenSCs was not correlated with IDO activity as these cells showed the high IDO activity following IFN&gamma; treatment.<br /> Conclusion: Although augmentation of T cell proliferation by MenSCs can be a basis for maintenance of endometrial homeostasis to cope with ascending infections, this may not fulfill the requirement for immunological tolerance to a semi-allogeneic fetus. However, more investigation is needed to examine whether or not the immunomodulatory properties of these cells are affected by endometrial microenvironment during pregnancy.</p> Endometrium, Immunological tolerance, Menstrual blood stem cells, Pregnancy, Proliferation, T lymphocytes 183 191 https://www.ajmb.org/En/Article.aspx?id=10363 https://www.ajmb.org/PDF/En/FullText/10363.pdf MehdiAleahmadDepartment of Immunology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran11413AlirezaGhanavatinejadDepartment of Immunology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran11414MahmoodBozorgmehrOncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran645Mohammad-RezaShokriDepartment of Immunology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran11416ShohrehNikooImmunology Research Center (IRC), Iran University of Medical Sciences, Tehran, Iran644MaryamTavakoliReproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran854SomaiehKazemnejadReproductive Biotechnology Research Centre, Avicenna Research Institute, ACECR, Tehran, Iran64FazelShokriDepartment of Hybridoma, Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran5Amir-HassanZarnaniReproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran7